Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H14ClN3O4S.2H2O |
| Molecular Weight | 403.838 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.[H][C@]12SCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=CC=C3)C(O)=O
InChI
InChIKey=USZXYXZHDWIZME-YVFQMZCUSA-N
InChI=1S/C15H14ClN3O4S.2H2O/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7;;/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23);2*1H2/t9-,10-,14-;;/m1../s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290
Curator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290
Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5748 |
1.15 mM [Ki] | ||
Target ID: CHEMBL4605 |
4.52 mM [Ki] | ||
Target ID: CHEMBL1743125 |
65.0 µM [Ki] | ||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date2002 |
|||
| Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date2002 |
|||
| Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date2002 |
|||
| Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date2002 |
|||
| Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date2002 |
|||
| Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date2002 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: |
Other AEs: Hypersensitivity... Other AEs: Hypersensitivity (1.5%) Sources: |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: |
Other AEs: Creatinine serum increased... Other AEs: Creatinine serum increased (1 patient) Sources: |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Other AEs: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased (1 patient) Sources: ALT increased (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Other AEs: Eosinophilia, Pruritus genital... Other AEs: Eosinophilia (1 patient) Sources: Pruritus genital (1 patient) Moniliasis (1 patient) Vaginitis (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Other AEs: Alkaline phosphatase increased, Blood urea increased... Other AEs: Alkaline phosphatase increased (1 patient) Sources: Blood urea increased (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: |
Other AEs: Diarrhea... Other AEs: Diarrhea (1 patient) Sources: |
20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: |
unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: |
Other AEs: Reaction serum sickness-like... Other AEs: Reaction serum sickness-like (0.5%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hypersensitivity | 1.5% | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: |
| Creatinine serum increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: |
| ALT increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
| Aspartate aminotransferase increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
| Eosinophilia | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
| Moniliasis | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
| Pruritus genital | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
| Vaginitis | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
| Alkaline phosphatase increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
| Blood urea increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
| Diarrhea | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: |
| Reaction serum sickness-like | 0.5% | 20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: |
unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Levofloxacin: an updated review of its use in the treatment of bacterial infections. | 2002 |
|
| Immunoglobulin E binding determinants on beta-lactam drugs. | 2002 Aug |
|
| [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001]. | 2002 Dec |
|
| An unusual abdominal mass in a renal transplant recipient. | 2002 Dec |
|
| Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children. | 2002 Jul |
|
| Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. | 2002 Jul |
|
| Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. | 2002 Jul |
|
| [Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999]. | 2002 Jun |
|
| The fecal microflora of 1-3-month-old infants during treatment with eight oral antibiotics. | 2002 Jun |
|
| Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. | 2002 Jun |
|
| Trends in antimicrobial susceptibility of the Streptococcus milleri group. | 2002 Jun |
|
| [Urinary antimicrobial prophylaxis]. | 2002 May |
|
| beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. | 2002 Nov |
|
| A case of purpuric drug eruption due to cefaclor. | 2002 Nov |
|
| An evaluation of cefaclor in Pakistani children with pharyngotonsillitis. | 2002 Oct |
|
| [Antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated in major hospitals in Nagano Prefecture]. | 2002 Oct |
|
| Cefaclor induced serum sickness like reaction. | 2002 Oct |
|
| Mycobacterium bohemicum cervical lymphadenitis. | 2002 Oct |
|
| The Italian Epidemiological Survey 1997-1999. Antimicrobial susceptibility data of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis in Italy. | 2002 Oct |
|
| Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains. | 2002 Sep |
|
| Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. | 2002 Sep |
|
| Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor. | 2002 Sep |
|
| Synthesis and biological activity of tris- and tetrakiscatecholate siderophores based on poly-aza alkanoic acids or alkylbenzoic acids and their conjugates with beta-lactam antibiotics. | 2003 |
|
| Drainage of liver abscess via laparoscopic trocar with local anesthesia. | 2003 Apr |
|
| Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea. | 2003 Apr |
|
| Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. | 2003 Aug |
|
| Modelling and analysing exchangeable binary data with random cluster sizes. | 2003 Aug 15 |
|
| Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains. | 2003 Feb |
|
| Low plasma cefaclor levels in cystectomized bladder cancer patients with various types of urinary diversion. | 2003 Feb |
|
| Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica typhimurium with mutations in both gyrA and parC. | 2003 Feb |
|
| [In vitro sensitivity to antimicrobial agents of Haemophilus influenzae strains isolated from clinical specimens]. | 2003 Jan |
|
| [Antibiotic resistance and serotype distribution of Streptococcus pneumoniae strains isolated from patients at Hacettepe University Medical Faculty]. | 2003 Jan |
|
| A case of baboon syndrome associated with group a streptococcal infection. | 2003 Jan |
|
| Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin. | 2003 Jan |
|
| Effect of extended-spectrum beta-lactamases on the susceptibility of Haemophilus influenzae to cephalosporins. | 2003 Jan |
|
| Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection. | 2003 Jan 15 |
|
| Determination of cefaclor in human plasma by a sensitive and specific liquid chromatographic-tandem mass spectrometric method. | 2003 Jan 25 |
|
| Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii. | 2003 Jul |
|
| Antimicrobial resistance in Gram-negative bacteria from Intensive Care Units and Urology Services. A nationwide study in The Netherlands 1995-2000. | 2003 Jun |
|
| Reactive metabolites and adverse drug reactions: clinical considerations. | 2003 Jun |
|
| How can we predict bacterial eradication? | 2003 Mar |
|
| A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis. | 2003 Mar |
|
| [Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics]. | 2003 Mar |
|
| Effect of computerised prescribing on use of antibiotics. | 2003 Mar 3 |
|
| Surveillance of antibiotic resistance in clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 2000-2001. | 2003 Mar-Apr |
|
| [Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penisillin-resistant Streptococcus pneumoniae between 1998 and 2000 in the Kinki district]. | 2003 May |
|
| Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux. | 2003 May |
|
| Rapid and sensitive high-performance liquid chromatographic determination of four cephalosporin antibiotics in pharmaceuticals and body fluids. | 2003 May 5 |
|
| [Hypersensitivity reactions to beta-lactam antibiotics in childhood]. | 2003 May-Jun |
|
| Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. | 2003 Spring |
Sample Use Guides
The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
Route of Administration:
Oral
Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70919498
Created by
admin on Sat Dec 16 08:29:22 GMT 2023 , Edited by admin on Sat Dec 16 08:29:22 GMT 2023
|
PRIMARY | |||
|
M96BT853SD
Created by
admin on Sat Dec 16 08:29:22 GMT 2023 , Edited by admin on Sat Dec 16 08:29:22 GMT 2023
|
PRIMARY | |||
|
91828-55-6
Created by
admin on Sat Dec 16 08:29:22 GMT 2023 , Edited by admin on Sat Dec 16 08:29:22 GMT 2023
|
PRIMARY | |||
|
185132
Created by
admin on Sat Dec 16 08:29:22 GMT 2023 , Edited by admin on Sat Dec 16 08:29:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
